Effect of treatment with L-Carnitin versus no treatment on the stage of disease in patients with nonalcoholic fatty liver

Effect of treatment with L-Carnitin versus no treatment on the stage of disease in patients with nonalcoholic fatty liver: a single blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201610069014N121

Enrollment

120

Registered

2016-10-08

Start date

2016-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Routine treatment plus oral L-Carnitin 1 gr per day for 6 months. Intervention 2: Just routine treatment.

Treatment - Drugs

Routine treatment plus oral L-Carnitin 1 gr per day for 6 months

Just routine treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Affected with nonalcoholic fatty liver. Exclusion criteria: Using methotrexate medication; viral hepatitis; hyperthyroidisms; hypothyroidisms; uncontrolled diabetes.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Assessing the stage of disease. Timepoint: before and 6 months after treatment. Method of measurement: using liver sonography.	—

Secondary

Measure	Time frame
Assessing liver enzymes. Timepoint: before and 6 months after treatment. Method of measurement: using laboratory tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaed Karimdadi

Shahid Beheshti Hospital

saedkid@yahoo.com+98 81 3838 0283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026